2025
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD
Yao F, He M, Wang J, Li Y, Zhang Q, Yang J, Wu J, Zhang Q, Zhou R, Zhang M, Meng L, Wu L, Chu Z, Hu W. Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD. Expert Opinion On Investigational Drugs 2025, 34: 435-447. PMID: 40411316, DOI: 10.1080/13543784.2025.2510671.Peer-Reviewed Original ResearchConceptsMild to moderate ADAnti-atopic dermatitisAdult patientsHealthy subjectsPDE4 inhibitorsPhase I clinical trialWell-tolerated treatmentOpen-label trialDouble-blindPlacebo-ControlledSafety profileAdverse eventsEASI scoreClinical developmentPharmacokinetic analysisAtopic dermatitisHealthy individualsPatientsPharmacokineticsDrug concentrationsEczema severityQuality of lifeEfficacyTrialsOintmentTralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.
Greenberg A, Shahriari M, Cameron M, Payette M, Dasilva D, Damiani G, Herman E, Eminger L, Issa N, Rodriguez A, Del Rosso J, Kang Y, Cohen J, Bunick C. Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series. The Journal Of Clinical And Aesthetic Dermatology 2025, 18: 16-19. PMID: 40538523, PMCID: PMC12175839.Peer-Reviewed Original ResearchInvestigator's Global AssessmentAdverse eventsFood and Drug AdministrationAtopic dermatitisInterleukin-4Alternative therapiesSwitching to alternative therapiesSurface area of involvementDiscontinuation of dupilumabDiscontinuation of treatmentT cell populationsChronic inflammatory skin conditionMulti-center case seriesUnited States Food and Drug AdministrationStates Food and Drug AdministrationBody surface areaOptimal clinical outcomesInflammatory skin conditionAD signsTargeting interleukins 4Area of involvementSystemic treatmentT cellsCase seriesClinical outcomesIs Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
Alani O, Wang D, Wahood S, Obagi S, Dasilva D, Zirwas M, Galimberti F, Bunick C. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis. Journal Of Drugs In Dermatology 2025, 24: 530-533. PMID: 40327575, DOI: 10.36849/jdd.9049.Peer-Reviewed Original ResearchConceptsUPA-treated patientsVenous thromboembolismVenous thromboembolism ratesAdverse cardiovascular eventsChronic inflammatory diseaseAtopic dermatitisMACE rateCardiovascular eventsClinical trialsInflammatory diseasesLong-term MACE rateIncidence rateImpact of upadacitinibPersistent systemic inflammationRisk of cardiovascular diseaseSystemic inflammationAD-related inflammationLower MACEBackground incidence ratesUpadacitinibJAK1 inhibitionPatientsThromboembolismCardiovascular diseaseMACEReal-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Rønnstad A, Bunick C, Chovatiya R, Kamata M, Nielsen M, Isufi D, Thomsen S, Vestergaard C, Wollenberg A, Egeberg A, Thyssen J, Loft N. Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis. American Journal Of Clinical Dermatology 2025, 26: 411-424. PMID: 40045152, DOI: 10.1007/s40257-025-00927-x.Peer-Reviewed Original ResearchConceptsProportion of patientsSafety of tralokinumabEASI-50EASI-75EASI-90Adverse eventsTreating moderate-to-severe atopic dermatitisAtopic dermatitisModerate-to-severe atopic dermatitisEczema Area and Severity IndexBio-experienced patientsTreatment of atopic dermatitisMeta-analysisMethodsWe systematically searched PubMedWeeks of treatmentFirst-in-classSystematic reviewSystematically searched PubMedClinical responseBio-naiveClinical trialsPrimary outcomeTralokinumabSecondary outcomesPatientsEfficacy and Safety of Ruxolitinib Cream Monotherapy in Patients Aged 2 Years and Older With Mild-to-Moderate Atopic Dermatitis: Results From 3 Large Randomized Phase 3 Studies
Simpson E, Eichenfield L, Papp K, Kircik L, Blauvelt A, Gold L, Zaenglein A, Lee L, Bunick C, Forman S, Holland K, Kallender H, Sturm D, Ren H, Armstrong A. Efficacy and Safety of Ruxolitinib Cream Monotherapy in Patients Aged 2 Years and Older With Mild-to-Moderate Atopic Dermatitis: Results From 3 Large Randomized Phase 3 Studies. Journal Of Allergy And Clinical Immunology 2025, 155: ab199. DOI: 10.1016/j.jaci.2024.12.618.Peer-Reviewed Original Research
2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry
Silverberg J, Calimlim B, Grada A, Bunick C, Gooderham M, Shi V, Obi C, Knapp K, Munoz B, Crawford J, Paller A. Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry. Journal Of Dermatological Treatment 2024, 35: 2428729. PMID: 39662888, DOI: 10.1080/09546634.2024.2428729.Peer-Reviewed Original ResearchPCR104 Asthma Characteristics and Patient-Reported Outcomes in Patients With Atopic Dermatitis in the Rapid Registry of Dupilumab Use in a Real-World Setting
Mosnaim G, Peters A, Lugogo N, Price D, Côté A, Plaza V, Xia C, Gómez L, Kwah J. PCR104 Asthma Characteristics and Patient-Reported Outcomes in Patients With Atopic Dermatitis in the Rapid Registry of Dupilumab Use in a Real-World Setting. Value In Health 2024, 27: s525. DOI: 10.1016/j.jval.2024.10.3347.Peer-Reviewed Original ResearchChemical, Biochemical, and Structural Similarities and Differences of Dermatological cAMP Phosphodiesterase-IV Inhibitors
Wang J, Ho M, Bunick C. Chemical, Biochemical, and Structural Similarities and Differences of Dermatological cAMP Phosphodiesterase-IV Inhibitors. Journal Of Investigative Dermatology 2024, 145: 1471-1488.e1. PMID: 39608668, PMCID: PMC12103293, DOI: 10.1016/j.jid.2024.10.597.Peer-Reviewed Original ResearchTreatment of psoriasisTopical treatmentAtopic dermatitisTopical treatment of atopic dermatitisIncreased cellular cAMP concentrationOral treatment of psoriasisPDE4 inhibitorsTopical treatment of psoriasisTreatment of atopic dermatitisCellular cAMP concentrationAnti-inflammatory effectsPhosphodiesterase-IV inhibitorImmune cellsOral treatmentPDE4 inhibitionSeborrheic dermatitisInflammatory responseCAMP concentrationAdenosine monophosphateRoflumilastDuration of cAMP signalingPDE4CAMP SignalingDermatitisApremilastUtilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States
Bunick C, Vleugels R, Lebwohl M, Grada A, Yue E, Wegrzyn L, D'Andrea E. Utilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States. SKIN The Journal Of Cutaneous Medicine 2024, 8: s448. DOI: 10.25251/skin.8.supp.448.Peer-Reviewed Original ResearchSystemic corticosteroid treatmentSystemic corticosteroidsAtopic dermatitisLong-term usersAdvanced therapiesContinuous health insurance enrollmentUsage of non-steroidal anti-inflammatory drugsRelevant proportion of patientsManagement of atopic dermatitisOral systemic corticosteroidsSystemic corticosteroid exposureClinical guidelinesHistory of malignancyProportion of patientsImmuno-mediated diseasesNon-steroidal anti-inflammatory drugsPercentage of patientsAtopic dermatitis patientsIntroduction of advanced therapiesAdvanced systemic treatmentsPopulation-based studyAnti-inflammatory drugsShort-term usersPrescription of biologicsCorticosteroid exposureLong-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies
Issa N, Chovatiya R, Talia J, Torres T, Eyerich K, Calimlim B, Yang Y, Pechonkina A, Moreira A, Grada A, Bunick C. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. SKIN The Journal Of Cutaneous Medicine 2024, 8: s449. DOI: 10.25251/skin.8.supp.449.Peer-Reviewed Original ResearchAtopic dermatitisModerate-to-severe atopic dermatitisLong-term disease controlClinically meaningful responseProlonged systemic therapyProportion of patientsUpadacitinib treatmentOptimal treatment targetsSystemic therapyOptimal treatmentMeaningful responseJAK inhibitorsInterim analysisPatientsUpadacitinibLong-term maintenanceTreatment targetItchingOptimal outcomesWeeksDermatitisDisease controlOutcomesSkinPhase 3Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry
Silverberg J, Gooderham M, Bunick C, Calimlim B, Grada A, Muñoz Maldonado Y, Li A, Fergestrom N, Simpson E. Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s450. DOI: 10.25251/skin.8.supp.450.Peer-Reviewed Original ResearchDermatology Life Quality IndexPP-NRSGlobal Assessment ScaleFollow-up visitAtopic dermatitisQuality of lifeReal-world outcomesSkin clearanceLongitudinal analysisRating ScalePeak Pruritus Numerical Rating ScaleInvestigator Global Assessment scaleSix-month follow-up visitPruritus Numerical Rating ScaleClear/almost clear skinEffect of upadacitinibNon-interventional registryDermatology Life Quality Index scoresNumerical rating scaleAssessment ScaleRegistry of adultsTreating atopic dermatitisEveryday clinical practiceLife Quality IndexImpact of ADSwitching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study
Bunick C, Magnolo N, Moore A, Xinghua G, Lynde C, Ibrahim N, Grada A, Levy G, Calimlim B, Wu X, Armendariz Y, Eyerich K. Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study. SKIN The Journal Of Cutaneous Medicine 2024, 8: s451. DOI: 10.25251/skin.8.supp.451.Peer-Reviewed Original ResearchAtopic dermatitisSafety resultsInadequate responseEczema Area and Severity IndexWeeks post-switchEczematous skin lesionsOral Janus kinaseEffective treatment strategiesClinically Meaningful ImprovementsClinically Meaningful OutcomesJanus kinaseChronic skin diseaseOptimal treatment targetsClinical responseMonotherapy studiesSkin clearanceSafety profileDupilumabTreatment strategiesInterleukin-13Interleukin-4UpadacitinibSafety signalsSwitch groupInterleukin-13 signalingWhy Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry
Silverberg J, Bunick C, Calimlim B, Grada A, Knapp K, Munoz B, Crawford J, Obi C, Paller A. Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s461. DOI: 10.25251/skin.8.supp.461.Peer-Reviewed Original ResearchPatient-reported outcomesTreat-to-target recommendationsSkin clearanceAtopic dermatitisOptimal treatmentSkin severityNRS-sleepSkin lesionsNRS painOptimal patient outcomesPartial improvementPatient outcomesNear-complete resolutionAtopic dermatitis treatmentReal-world studyMinimal itchingVIGA-ADOptimal treatment targetsEczema/atopic dermatitisDLQI 0/1Logistic regression modelsCross-sectional analysisItch severityOdds ratioDermatitis treatmentAchievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s459. DOI: 10.25251/skin.8.supp.459.Peer-Reviewed Original ResearchPP-NRSPatient Oriented Eczema MeasurePhase 3 trialAtopic dermatitisWeek 8Eczema Area and Severity Index scorePeak Pruritus Numerical Rating ScaleBody surface area involvementPruritus Numerical Rating ScaleInvestigator's Global AssessmentNumerical rating scaleSurface area involvementSeverity Index scoreSleep disturbanceAnalyzed post hocSleep improvementImprovement of sleepTapinarof creamEvaluate sleep disturbancesSuperior efficacySleep disturbance scoresArea involvementTapinarofItchingGlobal assessmentWorldwide Clinical and Real-World Exposure to Baricitinib
Vleugels R, Craiglow B, Mostaghimi A, Olsen E, Sontag A, Denning K, Somani N, Hordinsky M. Worldwide Clinical and Real-World Exposure to Baricitinib. SKIN The Journal Of Cutaneous Medicine 2024, 8: s501. DOI: 10.25251/skin.8.supp.501.Peer-Reviewed Original ResearchLength of therapyClinical trialsAtopic dermatitisTreated with baricitinibAverage length of therapyAge 2 yearsJuvenile idiopathic arthritisYears of ageMonths of ageBaricitinib doseAverage daily doseYrs of agePediatric patientsAcute infectious diseaseDaily doseCOVID-19 infectionAlopecia areataJAK inhibitorsHospitalized patientsIdiopathic arthritisBaricitinibPatientsBlind trialRheumatoid arthritisDisease statesACHIEVEMENT OF ITCH-FREE STATE AND SLEEP IMPROVEMENT WITH TAPINAROF IN TWO PIVOTAL ATOPIC DERMATITIS TRIALS
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. ACHIEVEMENT OF ITCH-FREE STATE AND SLEEP IMPROVEMENT WITH TAPINAROF IN TWO PIVOTAL ATOPIC DERMATITIS TRIALS. Annals Of Allergy Asthma & Immunology 2024, 133: s9. DOI: 10.1016/j.anai.2024.08.055.Peer-Reviewed Original ResearchPatient Oriented Eczema MeasurePP-NRSAtopic dermatitisWeek 8Sleep disturbancePeak Pruritus Numerical Rating ScalePruritus Numerical Rating ScaleNumerical rating scaleAnalyzed post hocStatistically significant improvementEvaluate sleep disturbancesRating ScaleSleep improvementTapinarofWeek 1Itch reductionScore improvementTreatment groupsBaseline scoresItchingWeeksPost-hocSleepPatientsOutcomesEfficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)
Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). British Journal Of Dermatology 2024, 192: 36-45. PMID: 39438067, DOI: 10.1093/bjd/ljae404.Peer-Reviewed Original ResearchAtopic dermatitisSecondary endpointsDose escalationOpen-labelClinical responseSafety profile of upadacitinibSafety signalsResponse to systemic therapyPruritus Numerical Rating ScaleSafety of upadacitinibEczematous skin lesionsWeeks of treatmentNumerical rating scaleSeverity Index reductionsChronic skin diseasePost Hoc AnalysisPhase 3b/4Systemic therapyItch responseSystemic treatmentPrimary endpointEczema AreaDupilumabSafety profileSuperior efficacyImpact of Atopic Dermatitis (Eczema) and Its Treatment on the Risk of Adverse Events Following Total Knee Arthroplasty
Smith-Voudouris J, Dhodapkar M, Halperin S, Cohen J, Grauer J. Impact of Atopic Dermatitis (Eczema) and Its Treatment on the Risk of Adverse Events Following Total Knee Arthroplasty. JAAOS Global Research And Reviews 2024, 8: e23.00267. PMID: 39436712, PMCID: PMC11498930, DOI: 10.5435/jaaosglobal-d-23-00267.Peer-Reviewed Original ResearchConceptsAtopic dermatitisAdverse eventsOdds of pneumoniaTotal knee arthroplastyPerioperative outcomes of patientsModerate-to-severe diseaseIncreased oddsEmergency departmentUrinary tract infectionChronic inflammatory skin conditionOutcomes of patientsLog-rank testRisk of adverse eventsInflammatory skin conditionIncreased odds of pneumoniaKnee arthroplastyTotal knee arthroplasty patientsPerioperative outcomesImmunosuppressive medicationsTract infectionsAggregate adverse eventsAdult patientsImpact of atopic dermatitisPatient characteristicsMultivariate analysisBipolar disorder among individuals with atopic dermatitis: a case–control study in the All of Us Research Program
Wride A, Chen G, Fan R, Leasure A, Jones S, Levey D, Damsky W, Cohen J. Bipolar disorder among individuals with atopic dermatitis: a case–control study in the All of Us Research Program. Clinical And Experimental Dermatology 2024, 50: 760-763. PMID: 39425681, DOI: 10.1093/ced/llae451.Peer-Reviewed Original ResearchJAK Inhibitors as Immunomodulators
Peterson D, Damsky W, King B. JAK Inhibitors as Immunomodulators. 2024, 57-71. DOI: 10.1007/978-3-031-66590-5_5.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply